Bioventus Inc. (NASDAQ: BVS) reported Q2 EPS of $0.21, in-line with the analyst estimate of $0.21. Revenue for the quarter came in at $147.7 million versus the consensus estimate of $146.28 million.

GUIDANCE:

Bioventus Inc. sees FY2025 EPS of $0.64-$0.68, versus the consensus of $0.66. Bioventus Inc. sees FY2025 revenue of $560-570 million, versus the consensus of $565.4 million.

For earnings history and earnings-related data on Bioventus Inc. (BVS) click here.